A real‐world study was conducted by enrolling patients aged 0–18 years who were diagnosed with CD19‐positive B‐ALL and treated with blinatumomab between January 2021 and May 2023 from 14 centers in China. Here, CD19 is linked to acute lymphoblastic leukemia.